Neoadjuvant chemotherapy enabling resection of stage IVA thymoma with myasthenia gravis and systemic lupus erythematosus: a case report - Takeaways - MDSpire

Neoadjuvant chemotherapy enabling resection of stage IVA thymoma with myasthenia gravis and systemic lupus erythematosus: a case report

  • By

  • Carlos A. Cedeno

  • Edgardo Santiago

  • Alex R. Cedeño

  • Jean Lafontaine

  • Maria J. Marcos

  • Omar Concepción

  • July 16, 2026

Share

  • 1

    Thymomas are rare tumors of the anterior mediastinum often associated with autoimmune diseases like myasthenia gravis and systemic lupus erythematosus.

  • 2

    A 32-year-old woman with stage IVA thymoma, myasthenia gravis, and systemic lupus erythematosus underwent neoadjuvant chemotherapy.

  • 3

    Neoadjuvant therapy resulted in significant clinical improvement and marked radiographic tumor regression in the patient.

  • 4

    The patient successfully underwent surgical resection with negative margins, confirming predominantly type B3 thymoma.

  • 5

    Postoperative radiotherapy was administered, and the patient achieved complete resolution of myasthenia gravis symptoms with no disease recurrence.

Original Source(s)

Neoadjuvant chemotherapy enabling resection of stage IVA thymoma with myasthenia gravis and systemic lupus erythematosus: a case report

  • by Carlos A. Cedeno, Edgardo Santiago, Alex R. Cedeño, Jean Lafontaine, Maria J. Marcos, Omar Concepción

  • July 16, 2026

Related Content

Occult cervical microinvasive squamous cell carcinoma with superficial endometrial spread mimicking high-grade squamous intraepithelial lesion in a postmenopausal woman: a case report

Age-stratified diagnostic performance of the ovarian-adnexal reporting and data system for adnexal masses: a focus on school-age children, early, and middle adolescents

Spinal metastases in geriatric patients: a retrospective single-center comparison of mortality and surgical outcomes following neurosurgical treatment